ArticleJournal of diabetes investigation2022
A novel mechanism of imeglimin-mediated insulin secretion via the cADPR-TRP channel pathway.
Article in Journal of diabetes investigation, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Imeglimin systematic review: a novel therapeutic approach for type 2 diabetes-unveiling benefits on β-cell function, insulin sensitivity, and potential long-term glycaemic control (HbA1c).European journal of clinical pharmacology · 2025Pooled it
- Efficacy, safety and tolerability of imeglimin in patients with type 2 diabetes mellitus: A meta-analysis of randomized controlled trials.Journal of diabetes investigation · 2023Pooled it
- Dual action of imeglimin on insulin secretion and sensitivity in type 2 diabetes.Diabetes, obesity & metabolism · 2026Trial
- Differential effects of imeglimin and metformin on insulin and incretin secretion-An exploratory randomized controlled trial.Diabetes, obesity & metabolism · 2025Trial
- Effect of Imeglimin, a Novel Anti-Diabetic Agent, on Insulin Secretion and Glycemic Variability in Type 2 Diabetes Treated with DPP-4 Inhibitor: A 16-Week, Open Label, Pilot Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Trial
- Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity.Endocrinology, diabetes & metabolism · 2022Trial
- Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects.Clinical drug investigation · 2022Trial
- Characterization of extracellular and membrane potentials in imeglimin-treated islets.Journal of diabetes investigation · 2026Article
- The Emerging Role of Mechanobiology in Connecting Metabolic and Cardiovascular Diseases: From Fundamentals to Future Therapies.Biomedicines · 2026Review
- Short-Term Glycemic Outcomes Associated with Imeglimin Use Among Patients with Type 2 Diabetes Mellitus: A Prospective Observational Study.Drug design, development and therapy · 2026Observational
- Similarities and differences in the intestinal actions of metformin and imeglimin.Diabetes, obesity & metabolism · 2025Article
- Imeglimin as an effective therapeutic approach in management of type 2 diabetes mellitus: an umbrella review and systematic review, meta-regression and meta-analysis.Diabetology & metabolic syndrome · 2025Review
- Imeglimin enhances glucagon secretion through an indirect mechanism and improves fatty liver in high-fat, high-sucrose diet-fed mice.Journal of diabetes investigation · 2024Article
- Imeglimin-mediated glycemic control in maternally inherited deafness and diabetes.Journal of diabetes investigation · 2023Article
- A large-scale functional analysis of genes expressed differentially in insulin secreting MIN6 sublines with high versus mildly reduced glucose-responsiveness.Scientific reports · 2023Article
- Improving the Effects of Imeglimin on Endothelial Function: A Prospective, Single-Center, Observational Study.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023Article
- Current understanding of imeglimin action on pancreatic β-cells: Involvement of mitochondria and endoplasmic reticulum homeostasis.Journal of diabetes investigation · 2023Article
- A Review on the Role of TRP Channels and Their Potential as Drug Targets_An Insight Into the TRP Channel Drug Discovery Methodologies.Frontiers in pharmacology · 2022Review
- A novel mechanism of imeglimin-mediated insulin secretion via the cADPR-TRP channel pathway.Journal of diabetes investigation · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
AIMS/
introductionImeglimin is a novel oral hypoglycemic agent that improves blood glucose levels through multiple mechanisms of action including the enhancement of glucose-stimulated insulin secretion (GSIS), however, the details of this mechanism have not been clarified. In the process of GSIS, activation of the transient receptor potential melastatin 2 (TRPM2) channel, a type of non-selective cation channel (NSCCs) in β-cells, promotes plasma membrane depolarization. The present study aimed to examine whether imeglimin potentiates GSIS via the TRPM2 channel in β-cells. MATERIALS AND
methodsPancreatic islets were isolated by collagenase digestion from male wild-type and TRPM2-knockout (KO) mice. Insulin release and nicotinamide adenine dinucleotide (NAD
resultsBatch-incubation studies showed that imeglimin enhanced GSIS at stimulatory 16.6 mM glucose, whereas it did not affect basal insulin levels at 2.8 mM glucose. Imeglimin increased the glucose-induced production of NAD
conclusionsImeglimin may activate TRPM2 channels in β-cells via the production of NAD
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.